Ascletis Pharma reports September share capital changes, option exercises

As of September 30, 2025, Ascletis Pharma Inc.'s authorized share capital remained at 7,000,000,000 ordinary shares with a par value of $0.0001, totaling $700,000. The company's total number of issued shares increased to 998,958,530 from 998,250,495 at the close of the preceding month.

This increase was primarily driven by the exercise of 708,035 share options under the Share Option Scheme approved on June 6, 2019, which raised HK$1,753,254 for the company. Concurrently, the number of outstanding share options under this scheme decreased to 7,643,653. Additionally, 650,000 options were granted under the 2025 Share Option Scheme, bringing its outstanding options to 5,470,175.

Furthermore, Ascletis Pharma Inc. reported repurchases of 800,000 ordinary shares for cancellation during April 2025, which were not yet cancelled as of September 30, 2025. These repurchases impact the total number of shares ultimately available.